These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17963128)

  • 21. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziconotide combination intrathecal therapy: rationale and evidence.
    Wallace MS; Rauck RL; Deer T
    Clin J Pain; 2010 Sep; 26(7):635-44. PubMed ID: 20639730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ziconotide for treatment of severe chronic pain.
    Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G
    Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.
    Wang YX; Pettus M; Gao D; Phillips C; Scott Bowersox S
    Pain; 2000 Feb; 84(2-3):151-8. PubMed ID: 10666519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
    Waites CR; Dominick MA; Sanderson TP; Schilling BE
    Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ziconotide: a new option for refractory pain.
    Prommer E
    Drugs Today (Barc); 2006 Jun; 42(6):369-78. PubMed ID: 16845440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration.
    Shields DE; Liu W; Gunning K; Montenegro R
    J Pain Symptom Manage; 2008 Jul; 36(1):e4-6. PubMed ID: 18538975
    [No Abstract]   [Full Text] [Related]  

  • 30. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
    Staats PS; Yearwood T; Charapata SG; Presley RW; Wallace MS; Byas-Smith M; Fisher R; Bryce DA; Mangieri EA; Luther RR; Mayo M; McGuire D; Ellis D
    JAMA; 2004 Jan; 291(1):63-70. PubMed ID: 14709577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of intrathecal ziconotide for the treatment of chronic pain.
    Jain KK
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2403-10. PubMed ID: 11060815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    Rauck RL; Wallace MS; Leong MS; Minehart M; Webster LR; Charapata SG; Abraham JE; Buffington DE; Ellis D; Kartzinel R;
    J Pain Symptom Manage; 2006 May; 31(5):393-406. PubMed ID: 16716870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps.
    Dupoiron D; Richard H; Chabert-Desnot V; Devys C; Leynia P; Boisdron-Celle M
    Neuromodulation; 2014 Jul; 17(5):472-82; discussion 482. PubMed ID: 24512055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A safety review of approved intrathecal analgesics for chronic pain management.
    Chalil A; Staudt MD; Harland TA; Leimer EM; Bhullar R; Argoff CE
    Expert Opin Drug Saf; 2021 Apr; 20(4):439-451. PubMed ID: 33583318
    [No Abstract]   [Full Text] [Related]  

  • 37. Intrathecal therapy: what has changed with the introduction of ziconotide.
    Kress HG; Simpson KH; Marchettini P; Ver Donck A; Varrassi G
    Pain Pract; 2009; 9(5):338-47. PubMed ID: 19740270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrathecal ziconotide for refractory pain.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jul; 13(7):875-7. PubMed ID: 15212625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.
    Bäckryd E; Sörensen J; Gerdle B
    Neuromodulation; 2015 Jul; 18(5):404-13. PubMed ID: 25879804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.